Literature DB >> 3680997

Experimental human infections with Giardia lamblia.

T E Nash1, D A Herrington, G A Losonsky, M M Levine.   

Abstract

Fifteen healthy volunteers were inoculated enterally with trophozoites of two distinct human isolates of Giardia lamblia, GS/M and Isr. Each of two groups of five volunteers were inoculated with 50,000 (GS/M or Isr) trophozoites. All of the volunteers inoculated with GS/M and none of the volunteers inoculated with Isr became infected. Three of five volunteers infected with GS/M became ill, including two who had diarrhea and typical symptoms of giardiasis. In the second study, three patients who were previously infected with GS/M and treated were rechallenged 12 weeks after the first inoculation, together with five new control volunteers. All of the latter group became infected, and two developed loose stools; two rechallenged volunteers became reinfected but were asymptomatic, and a third was retrospectively found to be infected at the time of challenge. Serum IgM, IgG, and IgA antibody responses to Giardia and intestinal fluid IgA antibody responses to Giardia occurred in 100%, 70%, 60%, and 50%, respectively, of infected volunteers. These studies fulfill Koch's postulates and demonstrate strain variation in the pathogenicity of Giardia infections in humans.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3680997     DOI: 10.1093/infdis/156.6.974

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  86 in total

Review 1.  Biology of Giardia lamblia.

Authors:  R D Adam
Journal:  Clin Microbiol Rev       Date:  2001-07       Impact factor: 26.132

2.  High-throughput Giardia lamblia viability assay using bioluminescent ATP content measurements.

Authors:  Catherine Z Chen; Liudmila Kulakova; Noel Southall; Juan J Marugan; Andrey Galkin; Christopher P Austin; Osnat Herzberg; Wei Zheng
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

3.  Identification of Conserved Candidate Vaccine Antigens in the Surface Proteome of Giardia lamblia.

Authors:  Barbara J Davids; Ching M Liu; Elaine M Hanson; Christine H Y Le; Jonathan Ang; Kurt Hanevik; Marvin Fischer; Matej Radunovic; Nina Langeland; Marcela Ferella; Staffan G Svärd; Majid Ghassemian; Yukiko Miyamoto; Lars Eckmann
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

4.  Α1-giardin based live heterologous vaccine protects against Giardia lamblia infection in a murine model.

Authors:  Gabriela Jenikova; Petr Hruz; Mattias K Andersson; Noa Tejman-Yarden; Patricia C D Ferreira; Yolanda S Andersen; Barbara J Davids; Frances D Gillin; Staffan G Svärd; Roy Curtiss; Lars Eckmann
Journal:  Vaccine       Date:  2011-10-12       Impact factor: 3.641

Review 5.  Intestinal mucosal responses to microbial infection.

Authors:  Lars Eckmann; Martin F Kagnoff
Journal:  Springer Semin Immunopathol       Date:  2005-06-01

Review 6.  Immunopathology of giardiasis.

Authors:  M J Farthing
Journal:  Springer Semin Immunopathol       Date:  1990

7.  Comparison of levels of inactivation of two isolates of Giardia lamblia cysts by UV light.

Authors:  Dong Li; Stephen A Craik; Daniel W Smith; Miodrag Belosevic
Journal:  Appl Environ Microbiol       Date:  2007-02-02       Impact factor: 4.792

8.  Comparison of Cytokine Responses in Ecuadorian Children Infected with Giardia, Ascaris, or Both Parasites.

Authors:  Jill Weatherhead; Andrea Arévalo Cortés; Carlos Sandoval; Maritza Vaca; Martha Chico; Sophia Loor; Philip J Cooper; Rojelio Mejia
Journal:  Am J Trop Med Hyg       Date:  2017-06       Impact factor: 2.345

9.  Multiplex assay detection of immunoglobulin G antibodies that recognize Giardia intestinalis and Cryptosporidium parvum antigens.

Authors:  Jeffrey W Priest; Delynn M Moss; Govinda S Visvesvara; Cara C Jones; Anna Li; Judith L Isaac-Renton
Journal:  Clin Vaccine Immunol       Date:  2010-09-28

10.  Giardiasis of the stomach.

Authors:  D M Berney; D Rampton; J D van der Walt
Journal:  Postgrad Med J       Date:  1994-03       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.